Patent SG-11201908977S-A (SG)
Title: Niraparib formulations
Inventor: MCGURK SIMON
IPC: C07D401/10
Filed: 2018-03-27
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 04 October 2018 (04.10.2018) W I PO I PCT Iiiimmoimiolollm onolomoniinomicionio oimIE (10) International Publication Number WO 2018/183349 Al (51) International Patent Classification: A61K 31/454 (2006.01) C07D 401/10 (2006.01) (21) International Application Number: PCT/US2018/024597 (22) International Filing Date: 27 March 2018 (27.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/477,425 27 March 2017 (27.03.2017) US (71) Applicant: TESARO, INC. [US/US]; 1000 Winter St. North #3300, Waltham, Massachusetts 02451 (US). (72) Inventors: MCGURK, Simon; c/o Tesaro, Inc., 1000 Winter St. North #3300, Waltham, Massachusetts 02451 (US). NARAYAN, Padma; c/o Tesaro, Inc., 1000 Win- ter St. North #3300, Waltham, Massachusetts 02451 (US). MEDENDORP, Clare; c/o Tesaro, Inc., 1000 Winter St. North #3300, Waltham, Massachusetts 02451 (US). WU, George; c/o Tesaro, Inc., 1000 Winter St. North #3300, Waltham, Massachusetts 02451 (US). RUDDY, Stephen; c/o Tesaro, Inc., 1000 Winter St. North #3300, Waltham, Massachusetts 02451 (US). KEMPINSKI, Heidi; c/o Tesaro, Inc., 1000 Winter St. North #3300, Waltham, Mass- achusetts 02451 (US). STEWART, Alistair; c/o Tesaro, Inc., 1000 Winter St. North #3300, Waltham, Massachusetts 02451 (US). (74) Agent: MCANDREW, Christopher W.; Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto, Cali- fornia 94304 (US). = (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.1700) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) (54) Title: NIRAPARIB FORMULATIONS (57) : The present invention relates to pharmaceutical capsule compositions comprising the compound niraparib as an active pharmaceutical ingredient, suitable for oral administration as well as to methods for their preparation. Also described herein are capsule formulations containing niraparib formed by the disclosed methods, and therapeutic uses of such capsule formulations for treating various disorders and conditions. The niraparib is distributed with substantial uniformity throughout a pharmaceutically acceptable carrier of the capsule formulations and exhibit good long-term stability and dissolution properties.